The trend toward fewer FDA advisory committee (AdCom) meetings is a mistake. AdComs force scientific debate into the open, providing a transparent check against the "my way or the highway" approach of powerful agency figures. Public hearings ensure regulatory decisions reflect a broader consensus, not just internal biases.

A significant disconnect exists between the FDA leadership's public statements promoting flexibility and the stringent, delay-prone reality faced by companies. For areas like gene therapy, firms report feeling the "rug was pulled out," suggesting investors should be skeptical of the agency's accommodating PR.

The new acting FDA commissioner, Kyle Diamantas, intends to increase the use of Advisory Committee meetings (AdComs). This is a significant procedural shift that suggests a move away from the previous leadership's more top-down, centralized decision-making. It signals a greater reliance on external experts and career staff, potentially leading to more transparent and predictable regulatory outcomes.

The FDA is creating a transparency paradox. It is increasingly publishing complete response letters (CRLs), giving insight into why drugs are rejected. Simultaneously, it has drastically cut the number of public advisory committee (AdCom) meetings held before approval decisions, reducing public input and pre-decision transparency.

While political drama at the top of the FDA captures headlines, the agency's rank-and-file reviewers are largely maintaining operational continuity. Many drug programs are still receiving necessary feedback within expected timeframes, suggesting the core machinery of the FDA is resilient.

Internal power shifts at the FDA, such as Vinay Prasad's rising influence, create a chilling effect on review teams. Even without direct orders, reviewers feel less emboldened to be flexible when leadership's public stance favors greater rigor. This 'tone from leadership' can shift regulatory outcomes more than explicit policy changes.

Senior FDA officials, both current and former, openly acknowledge that they select members for advisory committees (adcoms) who are likely to provide the results the agency desires. This practice of 'picking the jury' reveals a systemic bias, challenging the perception that adcoms are fully independent bodies and suggesting that the FDA has its 'finger on the scale' during these critical reviews.

Following the exit of controversial CBER director Vinay Prasad, the FDA approved several drugs that might have struggled under his tenure. This suggests a potential shift towards more regulatory flexibility, possibly influenced by political pressure ahead of midterm elections, creating opportunities for sponsors with controversial applications.

The current disconnect between the FDA leadership's public calls for flexibility and its divisions' strict actions is not new. For decades, the agency's hierarchy has acted as a promotional arm to encourage industry, while the review divisions have maintained a more conservative, old-school approach to rigor. This historical pattern is often overlooked.